Synemin (SYNM) is a type IV intermediate filament that has recently been shown to interact with the LIM domain protein zyxin, thereby possibly modulating cell adhesion and cell motility. Owing to this multiplicity of potential functions relevant to cancer development, we initiated a study to decipher SYNM expression and regulation in benign human breast tissue and breast cancer. Dot blot array analysis showed significant SYNM mRNA downregulation in 86% (n ¼ 100, Po0.001) of breast cancers compared with their normal tissue counterparts, a result that was confirmed by real-time PCR analysis (n ¼ 36, Po0.0001). Immunohistochemistry analysis showed abundant SYNM protein expression in healthy myoepithelial breast cells, whereas SYNM expression loss was evident in 57% (n ¼ 37, Po0.001) of breast cancer specimens. Next, we analyzed methylation of the SYNM promoter to clarify whether the SYNM gene can be silenced by epigenetic means. Indeed, methylation-specific PCR analysis showed tumor-specific SYNM promoter methylation in 27% (n ¼ 195) of breast cancers. As expected, SYNM promoter methylation was tightly associated (Po0.0001) with SYNM expression loss. Indepth analysis of the SYNM promoter by pyrosequencing showed extensive CpG methylation of DNA elements supposed to regulate gene transcription. Demethylating treatment of SYNM methylated breast cancer cell lines with 5-aza-2-deoxycytidine clearly reestablished the SYNM expression. Statistical analysis of the patient cohort showed a close association between SYNM promoter methylation and unfavorable recurrence-free survival (hazard ratio ¼ 2.941, P ¼ 0.0282). Furthermore, SYNM methylation positively correlated with lymph node metastases (P ¼ 0.0177) and advanced tumor grade (P ¼ 0.0275), suggesting that SYNM methylation is associated with aggressive forms of breast cancer. This is the first study on the epigenetic regulation of the SYNM gene in a cancer entity. We provide first hints that SYNM could represent a novel putative breast tumor suppressor gene that is prone to epigenetic silencing. SYNM promoter methylation may become a useful predictive biomarker to stratify breast cancer patients' risk for tumor relapse.
Introduction
Synemin (SYNM) is a type IV intermediate filament (IF), which was originally described as a desmin-and vimentin-binding protein in muscles (Granger and Lazarides, 1980) . The protein is widely expressed in most mammalian contractile cell types derived from the mesoderm and ectoderm, such as the heart, skeletal and small intestine muscle (Granger and Lazarides, 1980; Bilak et al., 1998; Mizuno et al., 2001; Titeux et al., 2001; Hirako et al., 2003) and also in certain noncontractile cells, such as glial cells and lens (Tawk et al., 2003) . Recently, it has become clear that SYNM contains binding motifs for various microfilamentassociated polypeptides such as a-actinin and vinculin, enabling the connection of IFs to microfilaments in the cytoskeleton context (Bellin et al., 1999 (Bellin et al., , 2001 Mizuno et al., 2001) . SYNM is related to the dystrophin complex and links the extracellular matrix to the IF network, maintaining the integrity of muscle cells (Blake and Martin-Rendon, 2002) .
IF proteins are key determinants for cell architecture and dynamics. Aberrant expression of, for example, desmin or the glial fibrillary acid protein may cause serious diseases, such as muscular dystrophy or neurodegenerative disorders (such as Alexander's disease), respectively (Herrmann et al., 2007) . Thus, it seems obvious that malfunction of the IF network could contribute to tumor development and malignancy. In fact, the SYNM binding partner protein vimentin was shown to be involved in the formation of microtentacles in breast cancer cell lines, and thereby likely acting as a critical factor for the metastatic spread of breast tumor cells (Whipple et al., 2008) . Recent work further showed that SYNM also binds to the LIM domain protein zyxin, which is essential for cell adhesion and cell migration (Beckerle, 1986; Sun et al., 2009 ):
In consequence, RNA interference-induced SYNM expression loss has been shown to cause reduction of cell adhesion in HeLa cells (Sun et al., 2009) .
Changes in cytoskeletal phenotypes such as decreased focal adhesion and increased cytoskeletal contraction can promote the translocation of tumor cells from the basal layer into stromal compartments, during epithelial-mesenchymal transition (Guarino, 2007) . These changes facilitate cell invasion and finally predict the ability of tumor cells to metastasize. Thus, epithelialmesenchymal transition and its related cytoskeletal organization may have a key role in tumor invasion biology (Guarino, 2007) . It has been shown that the lack of functional stress fiber network is capable of abating focal adhesion in breast cancer cells by suppressing key cytoskeletal proteins, such as TPM1 (Tropomyosin-1). TPM1 expression loss contributes to neoplastic transformation by conferring resistance to anoikis (Bharadwaj et al., 2005) . Escaping from anoikis could be a crucial advantage of metastatic tumor cells during organ invasion.
With regard to pathogenesis, SYNM has been shown to be differentially expressed in the human liver tissue during both progression of fibrosis and carcinogenesis: SYNM expression is upregulated in hepatic stellate cells of inflammatory diseases and in epithelial cells of intraheptic cholangiocarcinoma, but is abrogated in trabecular and pseudoglandular hepatocellular tumors. Hence, the SYNM expression pattern may help to delineate between different forms of fibrosis and liver cancer, respectively (Schmitt-Graeff et al., 2006) .
Apart from this, little is known about the potential role of SYNM in carcinogenesis; especially for human breast cancer, there is lack of information. For this reason, in this study, we present a comprehensive analysis of SYNM expression in human breast cancer. Intriguingly, we identified the IF-encoding gene SYNM as a target of epigenetic silencing by DNA promoter methylation and discussed its potential tumor-suppressive role for human breast tissue.
Results
Loss of SYNM mRNA expression in human breast cancer We have recently identified 4100 novel candidate genes differentially expressed in human breast cancer using bioinformatic in silico database mining procedures (Dahl et al., 2005) and DNA array-based expression profiling (Dahl et al., 2006) . In this approach, SYNM was detected as one of the most frequently downregulated genes, showing a substantial expression loss in 83% (fold change (FC)42) of breast carcinomas (data not shown). Therefore, we started a detailed analysis on SYNM expression and its potential implication in human breast cancer. A breast cancer dot blot array containing 100 complementary DNAs derived from 50 matching pairs of normal and tumor tissues was hybridized to a 32 P-labeled SYNM-specific complementary DNA probe (Figure 1a) . After densitometric evaluation, a significant (Po0.001) loss of SYNM mRNA expression could be detected in 86% of the analyzed breast carcinoma samples and also in 3 available corresponding lymph node metastases based on a FC2 approach. The significance of this differential expression is illustrated in Figure 1b . We confirmed this initial result by assessing an additional set of 31 breast tumors and 14 normal breast tissues for SYNM mRNA expression by real-time PCR analysis (Figure 1c ). In these breast carcinomas, strong downregulation of the SYNM expression could be detected (median FC ¼ 1044) as compared with the normal breast reference standard (Po0.0001).
SYNM protein expression in human breast cancer
Having found that SYNM RNA expression is abrogated in human breast cancer, we next aimed to characterize the SYNM protein expression in normal epithelial Aberrant SYNM promoter methylation in breast cancer E Noetzel et al breast tissues and breast carcinomas: We performed immunohistochemistry analysis using a well-established polyclonal SYNM antibody. We quantified SYNM protein staining according to the immunoreactive score (IRS) of Remmele and Stegner (1987) . SYNM staining was predominantly detected in the cytoplasm of myoepithelial cells of healthy breast lobules and ducts (Figures 2a and d) . Only a sporadic SYNM expression was present in the cytoplasm of luminal epithelial cells. In addition, we found abundant SYNM staining in contractile cells such as blood vessels, capillaries, as well as in nerve bundles and in parts in stromal cells of the connective tissue (see arrows in Figures 2a-c) . In contrast, invasive ductal carcinomas exhibited less and in major parts no SYNM staining at all in tumor cells (Figures 2b and e) .
We region (Figure 3a) , we analyzed whether promoter methylation could potentially account for SYNM expression loss observed in breast cancer. Methylationspecific PCR (MSP) technique was used to amplify a putative regulatory sequence within the CpG island, upstream (À387 to À250 bp) of the transcription start site ( þ 1) that contains a CCAAT-enhancer motif, a GC-box (Etienne et al., 1990 ) and a myc/max recognition site (Luscher, 2001) (Figure 3a) .
To verify the specificity and sensitivity of the applied MSP primers, we conducted a dilution experiment (Figure 3b ). The methylation-specific (M)-primer was able to detect 1% (0.1 ng) of methylated DNA in a large background of unmethylated DNA (99%, 9.9 ng), thus showing its high sensitivity to detect methylated SYNM DNA.
Next, we determined the methylation status of the SYNM promoter in 10 human breast cancer cell lines ( Figure 3c ) and correlated it with SYNM expression levels in these samples ( Figure 3d ). The two malignant breast cancer cell lines T47D and SKBR3 exhibited clear methylation of the SYNM promoter. Applying semiquantitative pyrosequencing analyses, we detected a methylation frequency of 26.9 and 37.5% in SKBR3 and T47D cells, respectively (Figure 3c ). In concordance with the methylation status, the SYNM expression was significantly reduced (Po0.001) in these two methylated cell lines compared with eight unmethylated breast cell lines (Figure 3d ).
To support the hypothesis that aberrant SYNM methylation contributes to SYNM gene silencing, we conducted in vitro demethylation experiments with three representative human breast cancer cell lines (namely ZR75-1, T47D and SKBR3) ( Figure 4a ). We observed that SYNM-methylated cell lines T47D and SKBR3 nearly completely lost SYNM methylation after demethylation treatment as shown by MSP. This result was confirmed by pyrosequencing technology. After 5-aza-2 0 -deoxycytidine (DAC) and trichostatin A (TSA) treatment, CpG methylation frequencies were 5.3 and 0% in SKBR3 and T47D cells, respectively ( Figure 4a ). Pyrograms of T47D and SKBR3 cells before and after treatment are shown in Figure 4b . In concordance with the MSP result, complete demethylation of each CpG duplet was evident in SKBR3 cells after DAC/TSA treatment. In contrast, promoter demethylation of T47D cells appeared incompletely, regarding five CpG positions. Coincidentally, this effect was predominant in CpGs (at positions 3, 14 and 15) located within the MSP primer-binding sites and consequently resulted in a residual methylation signal (mean: 5.3%, see Figure 4a ).
In accordance with effective demethylation of the SYNM promoter in these cell lines, SYNM mRNA Aberrant SYNM promoter methylation in breast cancer E Noetzel et al expression was clearly restored in SKBR3 and T47D cells, as quantified by real-time PCR (Figure 4c ). The measured increase of the SYNM expression was 21.8-and 43-fold in T47D and SKBR3 cells, respectively, and indicated that promoter demethylation can abrogate the apparent block of SYNM transcription in these two breast cancer cell lines. The marginal increased SYNM expression in the unmethylated cell line ZR75-1 after treatment was triggered most likely by the chromatinopening agent TSA. However, SYNM promoter demethylation increased SYNM gene expression on levels similar to those of originally unmethylated breast cancer cell lines (Figure 4d ). SYNM promoter methylation in primary human breast cancer Owing to SYNM promoter methylation found in breast cancer cell lines, we next analyzed whether promoter methylation may contribute to SYNM gene silencing in primary human breast cancer as well: Genomic DNA collected from a cohort of 195 breast cancer patients was analyzed for SYNM methylation by MSP technology. Representative methylation results are shown in Figure 5a . SYNM promoter methylation was found in 26.7% (52/195) of breast cancer specimens (for example, patient #90, #121, #164 in Figure 5a ). Accordingly, in 73.3% (143/195) of breast cancer specimens, only unmethylated DNA was detectable (for example, patients #4, #11, #34 in Figure 5a ). Normal breast tissues (n ¼ 10) were analyzed by MSP as well and did not show any SYNM promoter methylation (data not shown), indicating that this is a tumor-specific process. We further measured the methylation frequencies for each CpG duplet within the analyzed SYNM promoter sequence (137 bp) of 13 tumor samples, who showed clear SYNM methylation signals by MSP analysis (Figure 5b ). We observed continuous methylation of all 16 CpG duplets, even though methylation of the first 9 CpGs was quite higher (mean methylation: 13 ± 13.6%, range: 3.1-63.7%) than those of positions 10-16 (mean methylation: 7.0±8.2%, range: 1.8-30.9%). Pyrograms and matching MSP results for three representative samples (#45, #47 and #80) are shown in Figure 5b . Overall, there was a good concordance between MSP signal strengths and CpG methylation frequencies measured using the pyrosequencing technique (Figure 5b ).
SYNM promoter methylation is associated with loss of SYNM expression in human breast cancer specimens To analyze whether SYNM promoter methylation is associated with silencing of the SYNM expression in primary breast cancer, we measured mRNA expression Aberrant SYNM promoter methylation in breast cancer E Noetzel et al within that part of the breast cancer cohort previously used for methylation analysis for which mRNA was available (n ¼ 36). We compared the SYNM expression of unmethylated (n ¼ 14) and methylated (n ¼ 22) breast cancer specimens with that in a normal breast tissue standard (n ¼ 10) (Figure 6a ). In the normal breast tissue, the SYNM expression was relatively variable (expression range: 0.072-38.36) (Figure 6a ). We observed no significant (P40.05) downregulation of SYNM mRNA in unmethylated breast cancer specimens (median FC ¼ 28.1) compared with normal breast tissue (Figures 6a and b) . In contrast, there was strong loss (median FC ¼ 1299) of the SYNM expression in methylated tumors compared with both unmethylated tumors and normal breast tissues (Po0.001) (see box plot in Figure 6b ). In addition, the degree of SYNM downregulation correlated positively (Po0.0001) with the promoter methylation status in breast carcinomas (Table 2 ). This in turn underlined our observation that a strong SYNM expression loss occurred only in conjunction with aberrant SYNM promoter methylation.
Statistical analysis of clinical-pathological patient data and patient survival After characterizing our breast cancer cohort (Table 1) , we tested for associations between clinical-pathological characteristics and SYNM methylation status. SYNM promoter methylation is significantly associated with positive lymph node status (P ¼ 0.0177), tumor grading (P ¼ 0.0275) and loss of SYNM mRNA expression (Po0.0001). No associations were found between SYNM promoter methylation and other parameters, such as age at diagnosis, tumor size, histological tumor type and hormone receptor status (Table 2) . Next, we investigated the potential associations between SYNM methylation status, recurrencefree survival and overall survival (Table 3) . We found an increased risk of tumor recurrence in breast cancer patients who exhibited SYNM promoter methylation (Po0.0005), whereas patients without SYNM methylation had a better survival rate (Figure 7a) . SYNM promoter methylation is considerably associated Aberrant SYNM promoter methylation in breast cancer E Noetzel et al with a low 5-year RFS rate (29±12%), whereas patients without SYNM promoter methylation have a favorable 5-year RFS rate of 70 ± 6%. Expressed in time scales, patients with a methylated SYNM promoter showed a significantly reduced mean RFS time of 58.7 ± 7.1 months compared with 132.4 ± 6.8 months in those patients without SYNM methylation.
After subgrouping our cohort, we found that SYNM methylation has a strong prognostic value in nodepositive breast cancer patients (Figure 7b ). Patients with SYNM methylation and lymph nodes metastasis had a poorer RFS (mean RFS time: 47.4 ± 9 months, P ¼ 0.0094) compared with the node-positive patient group, without the SYNM methylation event (mean RFS time: 92.6 ± 8.5 months).
We directly compared the influence of SYNM promoter methylation on RFS prediction between node-positive and node-negative breast cancer patients (Figure 7d ): The group of lymph node-negative patients presented the best outcome for tumor relapse (5-year RFS rate: 81 ± 8%, mean RFS time: 120.1 ± 5 months) independent of SYNM promoter methylation status (Figures 7c and d) . Interestingly, we deciphered a favorable 5-year RFS rate of 62 ± 10% (mean RFS time: 92.6 ± 8.5 months) for lymph node-positive patients lacking SYNM promoter methylation, compared with those patients with SYNM methylation event (5-year RFS rate: 17 ± 11%, mean RFS time: 47.4 ± 9, Po0.0001) (Figure 7d ).
Finally, we tested for predictive independency of SYNM promoter methylation from other prognostic Elston and Ellis (1993) . e IRS according to Remmele and Stegner (1987) . Breast tissue samples used for DNA methylation and mRNA expression analyses were obtained from patients treated by primary surgery for breast cancer at the Departments of Gynecology at the University Hospitals of Aachen, Jena, Regensburg and Du¨sseldorf, Germany. The Institutional Review Boards of the participating centers approved the study. All patients gave informed consent to the study for retention and analysis of their tissue for research purposes. Sobin and Wittekind (1997) . d According to Bloom and Richardson, as modified by Elston and Ellis (1993) . e IRS according to Remmele and Stegner (1987) .
f Median FC of SYNM expression loss in the group of breast carcinomas. Significant P-values (o0.05) are marked in bold face.
Aberrant SYNM promoter methylation in breast cancer E Noetzel et al parameters in human breast cancer. We calculated a multivariate Cox regression model, including all factors (such as SYNM methylation, nodal status, tumor size, histological grading and progesterone receptor status), which influenced the RFS time of patients in our cohort of breast cancer (see Table 3 ). Cox regression confirmed SYNM promoter methylation to be a predictive independent marker for early tumor recurrence (Table 4) . Breast cancer patients with a methylated SYNM promoter have an estimated 2.9-fold increased risk for tumor relapse compared with patients without SYNM methylation event (hazard ratio ¼ 2.941, P ¼ 0.0282). No significant correlation was found between SYNM promoter methylation status and patients overall survival (Table 3) .
Discussion
Cell architecture and plasticity are determined by a highly dynamic regulation of IFs (Herrmann et al., 2007) .
Keratin mutations, for instance, are associated with various diseases, such as inflammatory bowel disease or muscular dystrophy (Omary et al., 2004) . Furthermore, it is assumed that the differential expression of IF proteins has an important role in tumor biology and invasion, as shown for vimentin in breast cancer (Whipple et al., 2008) and E-cadherin during epithelial-mesenchymal transition (Guarino, 2007) . The investigation of IF protein expression in human malignancies could hence improve our understanding of carcinogenesis. SYNM as a type IV IF, is supposed to modulate fundamental processes such as cell adhesion, cell motility in HeLa cells, due to its interaction with the LIM domain protein zyxin (Sun et al., 2009) . It is differential expressed in diseased liver tissue (Schmitt-Graeff et al., 2006; Van Rossen et al., 2009 ) and astrocytoma cells (Pan et al., 2008) , but its expression and regulation in other cancer entities has not been investigated so far. Thus, for the first time, we aimed to elucidate SYNM expression and regulation in human breast cancer.
Normal breast tissue showed abundant SYNM expression. In contrast, the SYNM expression was clearly downregulated in invasive breast cancer compared with the normal breast tissue analyzed both by complementary DNA dot blot array and real-time PCR analysis. At the protein level, the majority of SYNM protein was localized in the cytoplasm of myoepithelial cells, whereas minor amounts were found in luminal epithelial cells of the mammary gland tissue. This expression pattern is in line with the myoepithelial SYNM expression pattern in several mammalian muscle types (Hirako et al., 2003) and is also in agreement with its biological function, namely the maintenance of cell contractibility (Blake and Martin-Rendon, 2002) . Stageand tissue-specific expression of the SYNM protein could therefore be an important factor for normal tissue morphology and homeostasis, in the human breast, for example, during lactation, which requires contractibility of myoepithelial cells (Deugnier et al., 2002) . In contrast, SYNM protein expression was strongly reduced in the majority (70%) and even completely abrogated in 56% of invasive breast carcinomas. So far, a tumor-associated loss of the SYNM expression was only shown for epithelial tissue components of hepatocellular tumors (Schmitt-Graeff et al., 2006) . In summary, our expression data show that SYNM is clearly downregulated in human breast cancer, both at the mRNA and protein levels. Future studies are necessary to determine the precise time point when the SYNM expression is lost during breast cancer development.
With respect to its biological function, it is likely that SYNM expression loss could provoke serious impacts on morphology and functionality of myoepithelial cells. The association of SYNM with the dystrophin complex and its cancer-specific expression loss, could probably interrupt the conjunction between the extracellular matrix and IF network of myoepithelial breast cells. This, in turn, could decrease cell adhesion, could support metastatic spread and lead to tumor progression. Such an effect of cytoskeletal destabilization has already been described for the loss of TPM1 expression According to TNM classification by Sobin and Wittekind (1997). d According to Bloom and Richardson, as modified by Elston and Ellis (1993) .
e IRS according to Remmele and Stegner (1987) P-values (o0.05) are marked in bold face.
Aberrant SYNM promoter methylation in breast cancer E Noetzel et al in human breast cancer cell (Bharadwaj et al., 2005) . The myoepithelial cell layer is a key player in establishing and maintaining an epithelial breast architecture because of its major influence on luminal cell growth and differentiation (Deugnier et al., 2002) . Furthermore, well-differentiated myoepithelial breast cells are socalled 'natural tumor suppressors', (Lakhani and O'Hare, 2001 ) because of inhibition of angiogenesis, induction of growth arrest and apoptosis (Nguyen et al., 2000) . We addressed the molecular mechanism by which the SYNM expression is silenced in breast cancer. We identified a CpG-rich cluster and several conserved transcription-relevant DNA motifs within the SYNM promoter, indicating that CpG methylation of this specific DNA region could lead to repression of the SYNM gene. Tumor-specific SYNM promoter methylation was evident in two breast cancer cell lines (namely T47D and SKBR3) and in over one-fourth (26.7%) of patients with invasive breast cancer. In case of SYNM promoter methylation in patient samples, it affected each CpG duplet within the transcription factor recognition sites, providing evidence that this promoter region (À387 to À250 bp) contributes to SYNM gene silencing in human breast cancer.
Interestingly, there was a striking correlation between SYNM promoter methylation and SYNM expression: We found a significant loss of SYNM mRNA expression only in those breast cancer specimens that harbored a methylated SYNM promoter. Thus, we suggest that aberrant promoter methylation functions as the cardinal mechanism of SYNM gene silencing in human breast cancer. This argument is supported by the strong effect of in vitro demethylation on the SYNM promoter in which demethylated T47D and SKBR3 cells reexpress SYNM at levels comparable with those of unmethylated breast cell lines.
Although aberrant SYNM promoter methylation is not a highly frequent event in human breast cancer, we showed a clear prognostic value in case of incidence. Aberrant SYNM promoter methylation in breast cancer E Noetzel et al SYNM methylation was significantly associated with increased metastatic spread (positive lymph node status) and low tumor differentiation (grading). Furthermore, SYNM promoter methylation was strongly associated with reduced patients RFS and indicated an increased risk (hazard ratio ¼ 2.9) for tumor relapse, in contrast to the not significant association of SYNM methylation with patients overall survival. As SYNM methylation was associated with lymph node metastasis, we focused on these high-risk cancer patients and revealed further evidence of predictive importance: As expected, node-positive breast cancer patients showed a poor prognosis in our patient cohort, but in case of SYNM promoter methylation, the likelihood for early tumor relapse was even increased. Intriguingly, the fraction of node-positive breast cancer patients lacking SYNM methylation presented an unexpected favorable prognosis. Improved risk assessment in the group of node-positive breast cancer patients is urgently required. Recent studies have indicated that even patients with one to three positive lymph nodes may have such a favorable prognosis that adjuvant chemotherapy may be safely spared (Mook et al., 2009) .
Thus, SYNM promoter methylation could represent a novel predictive biomarker for risk assessment in the group of node-positive breast cancer patients and may have promise as a diagnostic tool for therapy optimization in the future.
The predictive quality of epigenetic markers has already been shown, that is, in case of tumor-specific methylation of the death-associated protein kinase depicting aggressive stage I nonsmall-cell lung cancer (Tang et al., 2000) .
Owing to its tumor-specific expression loss and its important biological function, SYNM could represent a novel tumor suppressor gene, which gets silenced because of aberrant promoter methylation in the course of breast cancer progression. However, functional analyses, that is, in vitro models, have to furnish proof of this proposed tumor-suppressive function in human breast cells.
Epigenetic silencing of tumor suppressor genes affecting the IF network and the cytoskeleton organization of cancer cells has already been shown for PAK3 methylation in lung cancer cell lines (Hoque et al., 2008) . With regard to human breast cancer, several tumor suppressor genes have been reported to get silenced by aberrant CpG methylation. These genes fall into various critical pathways provoking tumor formation, for instance, cell-cycle control (14-3-3s) (Ferguson et al., 2000) , DNA damage repair (BRCA1) (Dobrovic and Simpfendorfer, 1997) , cell adhesion (CDH1) (Caldeira et al., 2006) , steroid receptor signaling (ESR1, PGR) (Widschwendter and Jones, 2002) and cell differentiation (SFRP1 and SFRP2) (Veeck et al., 2006 . This class of epigenetically silenced tumor suppressor genes may represent new targets for improved cancer therapies due to the potential reversibility of CpG methylation events in vivo. Therapy approaches combining DNA methyl transferase and histone deacetylase inhibitors may minimize toxicity and increase therapeutic effects (Yang et al., 2001; Kristensen et al., 2009 ).
In conclusion, this is the first study providing evidence that SYNM may have a tumor-suppressive function in healthy breast tissue and that SYNM promoter methylation could serve as a new predictive marker for human breast cancer. For a better understanding of the contribution of SYNM to the initiation and progression of breast cancer, future studies have to focus on the cellular function of this IF molecule in benign and diseased breast tissues.
Materials and methods

Patient samples
Tumor tissue and macroscopically normal breast tissue were formalin fixed and paraffin embedded or snap frozen in liquid nitrogen immediately after surgery. Hematoxylin and eosin8-stained sections were prepared for assessment of the percentage of tumor cells; only samples with 470% tumor cells were further processed. The normal breast tissue used for standardization contained B40% of epithelial cells. We only processed tumor tissues obtained from patients who did not undergo any neoadjuvant chemotherapy. For patient characteristics, see Table 1 .
Cell lines
The human breast cell lines MCF10A, MCF12A, ZR75-1, HS-578T, BT20, MDA-MB231, MDA-MB468, MCF7, SKBR3 and T47D were obtained from the ATCC (American Type Culture Collection, Rockville, MD, USA) and cultured under recommended conditions. Sobin and Wittekind (1997) .
b IRS according to Remmele and Stegner (1987) . According to Bloom and Richardson, as modified by Elston and Ellis (1993) . Significant P-values (o0.05) are marked in bold face.
